AI MARKET SCANNING

Adicet Bio, Inc.

📅 Next Catalyst: Nov 05, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.06%
MAX GAP RECORD +9.36%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ACET
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
-4.91%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
+0.99%
Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE)
-0.85%
Nov 05, 2025 Earnings Release 2025-11-05 (AFTER CLOSE)
+0.00%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
-1.02%
May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE)
-0.50%
Mar 06, 2025 Earnings Release 2025-03-06 (AFTER CLOSE)
-3.07%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.2%
Bullish Gaps (4)
Bearish Gaps (6)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ACET

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗